Literature DB >> 11388240

Stentless bioprosthetic heart valve research: sheep versus primate model.

A Trantina-Yates1, C Weissenstein, P Human, P Zilla.   

Abstract

BACKGROUND: The mild inflammatory response against stented bioprosthetic heart valves in the sheep model is often opposed by a more distinct response in failing human implants. With the emergence of stentless root prostheses with their significantly larger proportion of tissue interacting with the immune system of the host, a more relevant animal model than the sheep may be needed.
METHODS: Valved, porcine aortic roots of 5 cm length were fixed in 0.2% glutaraldehyde and implanted in the upper descending aorta of Merino sheep (n = 5; 43+/-3 kg) and Chacma baboons (n = 5; 17+/-3 kg). After 6 weeks of tissue calcification, pannus outgrowth and inflammation were assessed by atomic absorption spectrophotometry, histologic damage scoring (0 to 3), image analysis, and transmission electron microscopy.
RESULTS: The main difference between the two animal models was in aortic wall calcification (64.8+/-39.8 microg/mg in the sheep model versus 4.1+/-5.9 microg/mg in the primate model; p > 0.005). In both models, leaflet calcification was negligible (2.6+/-2.4 microg/mg in the sheep versus 2.5+/-1.9 microg/mg in the primate), and the overall extent of inflammation was comparable (1.2+/-0.8 versus 0.98+/-0.7; p = 0.18 in the sheep and the primate, respectively). Qualitatively, the sheep demonstrated a macrophage-dominated reaction whereas the inflammatory demarcation often resembled a granulocyte-dominated xenograft response in the primate. Pannus outgrowth was comparable in length (8.4+/-2.3 mm versus 9.1+/-4.3 mm proximally and 7.1+/-3.4 mm versus 7.4+/-5.1 mm distally, in the sheep and baboon, respectively; p > 0.05).
CONCLUSIONS: Our results confirm the sheep as a significantly stronger calcification model for stentless aortic heart valves than the primate. Remaining antigenicity of porcine tissue as a result of incomplete cross-linking, however, elicits a distinctly stronger xenograft-type reaction in the primate model.

Entities:  

Mesh:

Year:  2001        PMID: 11388240     DOI: 10.1016/s0003-4975(01)02502-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Fixation of Bovine Pericardium-Based Tissue Biomaterial with Irreversible Chemistry Improves Biochemical and Biomechanical Properties.

Authors:  H Tam; W Zhang; D Infante; N Parchment; M Sacks; N Vyavahare
Journal:  J Cardiovasc Transl Res       Date:  2017-02-17       Impact factor: 4.132

2.  Pediatric cardiopulmonary bypass adaptations for long-term survival of baboons undergoing pulmonary artery replacement.

Authors:  Carrie Whittaker; Gary Grist; Arthur Bert; Kathleen Brasky; Stacy Neighbors; Christopher McFall; Stephen L Hilbert; William B Drake; Michael Cromwell; Barbara Mueller; Gary K Lofland; Richard A Hopkins
Journal:  J Extra Corpor Technol       Date:  2010-09

3.  A novel crosslinking method for improved tear resistance and biocompatibility of tissue based biomaterials.

Authors:  Hobey Tam; Will Zhang; Kristen R Feaver; Nathaniel Parchment; Michael S Sacks; Naren Vyavahare
Journal:  Biomaterials       Date:  2015-07-14       Impact factor: 12.479

4.  Bioengineered human and allogeneic pulmonary valve conduits chronically implanted orthotopically in baboons: hemodynamic performance and immunologic consequences.

Authors:  Richard A Hopkins; Arthur A Bert; Stephen L Hilbert; Rachael W Quinn; Kathleen M Brasky; William B Drake; Gary K Lofland
Journal:  J Thorac Cardiovasc Surg       Date:  2012-07-25       Impact factor: 5.209

5.  Assessing anticalcification treatments in bioprosthetic tissue by using the New Zealand rabbit intramuscular model.

Authors:  Gregory A Wright; Joelle M Faught; Jane M Olin
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

6.  The design and development of a stented tissue mitral and aortic heart valve replacement for human implantation.

Authors:  Murray Legg; Edward Mathews; Ruaan Pelzer
Journal:  Cardiovasc J Afr       Date:  2012-04       Impact factor: 1.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.